Author: Matt Mauney

Less than 13% of cancer patients who receive checkpoint inhibitor drugs such as Keytruda (pembrolizumab) and Opdivo (nivolumab) actually benefit from the much-heralded form of immunotherapy, new research shows. The modest response rate is part of the first broad study that has estimated the rise in patient eligibility and the actual benefit of this immunotherapy…

The post Study Finds Modest Reality of Immunotherapy for Cancer appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

A state jury in New York ordered Johnson & Johnson to pay $300 million in punitive damages to Donna Olson and her husband who claim its talcum powder caused her to develop mesothelioma. The same jury awarded the couple $25 million in compensatory damages a few days earlier. The total verdict is one of the…

The post Johnson & Johnson Hit with $325M Verdict in Talc-Mesothelioma Case appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.

The U.S. Food & Drug Administration on Thursday approved Tumor Treating Fields, a therapy involving electric currents that disrupt cancer cell division and inhibit tumor growth, for the first-line treatment of malignant pleural mesothelioma. It is the first treatment in more than 15 years that the FDA approves for mesothelioma. In 2004, the agency added…

The post FDA Approves First New Treatment for Mesothelioma in 15 Years appeared first on Mesothelioma Center – Vital Services for Cancer Patients & Families.